Editorial Commentary
Advances of HER2 testing for women with breast cancer
Translational Breast Cancer Research
2023;
4:
9
(31 January 2023)
Letter to the Editor
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER−PR+HER2−) breast cancer
Translational Breast Cancer Research
2023;
4:
8
(31 January 2023)
Review Article
Breast cancer gene expression signatures: development and clinical significance—a narrative review
Translational Breast Cancer Research
2023;
4:
7
(31 January 2023)
Review Article
Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer
Translational Breast Cancer Research
2023;
4:
6
(31 January 2023)
Original Article
A retrospective cohort study comparing reconstructive techniques and outcomes in post-mastectomy triple negative breast cancer patients
Translational Breast Cancer Research
2023;
4:
5
(31 January 2023)
Original Article
Molecular subtypes predict the prognosis of male breast cancer: a retrospective cohort study
Translational Breast Cancer Research
2023;
4:
4
(31 January 2023)
Original Article
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy
Translational Breast Cancer Research
2023;
4:
3
(31 January 2023)
Clinical Practice Guideline
Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022
Translational Breast Cancer Research
2023;
4:
2
(31 January 2023)
Meet the Professor
Zefei Jiang: when ideals illuminate reality, more breast cancer patients will benefit from the inclusion of T-DM1 in China’s national medical insurance catalog
Translational Breast Cancer Research
2023;
4:
1
(31 January 2023)
